Patents Assigned to Dr. Falk Pharma GmbH
  • Patent number: 11866505
    Abstract: Described herein are anti-CD30L antibodies and pharmaceutical compositions for the treatment of autoimmune diseases and disorders such inflammatory bowel disease (IBD), including Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Grant
    Filed: August 26, 2022
    Date of Patent: January 9, 2024
    Assignees: PROMETHEUS BIOSCIENCES, INC., DR. FALK PHARMA GMBH
    Inventors: Jessie-Farah Fecteau, Mark Renshaw, Johan Fransson, Olivier Laurent, Burton Barnett
  • Patent number: 11850252
    Abstract: The present invention relates to the use of Nor-UDCA in the treatment of hepatic steatosis in patients having a hepatic fat fraction of greater than 10%.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: December 26, 2023
    Assignee: DR. FALK PHARMA GMBH
    Inventors: Markus Pröls, Roland Greinwald, Michael Trauner, Peter Fickert
  • Patent number: 11738032
    Abstract: Disclosed is a storage-stable pharmaceutical formulation for rectal administration, containing budesonide or a pharmaceutically compatible salt or derivative thereof, and at least 80 wt % of a solid fat or a mixture of different solid fats, based on the total weight of the formulation, as well as at least one anti-oxidation agent that is compatible therewith.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: August 29, 2023
    Assignee: Dr. Falk Pharma GmbH
    Inventors: Rudolph Wilhelm, Markus Pröls, Roland Greinwald, Ralf Mohrbacher
  • Patent number: 11464733
    Abstract: Provided is an enema for rectal application containing budesonide as an active ingredient in order to treat an inflammatory bowel disease, or to prevent a relapse. The enema for rectal application contains budesonide as the active ingredient, in which 1.5 to 2.5 mg of budesonide per dose is administered twice a day for 12 weeks in order to treat an inflammatory bowel disease, or to prevent a relapse. The enema for rectal application comprises several doses whereby the most preferable dose of budesonide is 2.0 mg per dose. The enema for rectal application is taken in order to treat ulcerative colitis or Crohn's disease, or to prevent a relapse; has a foamy, more rigid to a more liquid, gel-like structure.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: October 11, 2022
    Assignee: DR. FALK PHARMA GMBH
    Inventors: Shoji Kondo, Morio Iwasaki, Yoji Yamada
  • Patent number: 11382860
    Abstract: Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: July 12, 2022
    Assignee: Dr. Falk Pharma GmbH
    Inventors: Roland Greinwald, Ralph Mueller, Markus Proels, Rudolf Wilhelm
  • Patent number: 11173121
    Abstract: An optimized pharmaceutical formulation for the treatment of inflammatory diseases of the colon is disclosed, wherein the pharmaceutical formulation is a capsule containing pellets, which capsule is suitable for oral administration and delivers the active substance in a targeted manner to the site of action, namely the colon. This is achieved by a complex and multiple coating of pellets, which permit a modified release of active substance. The release of the active substance is at its maximum only in the colon, with at the same time low blood plasma levels. The results of the pharmaceutical tests concerning in vitro release are corroborated by the results in pharmaco-kinetic and clinical studies and the clinical efficacy demonstrated by these. The formulation according to the invention has a very good medicinal safety.
    Type: Grant
    Filed: August 22, 2019
    Date of Patent: November 16, 2021
    Assignee: Dr. Falk Pharma GmbH
    Inventors: Rudolf Wilhelm, Markus Proels, Roland Greinwald, Tanju Nacak, Ansgar Boegershausen
  • Publication number: 20210228487
    Abstract: An optimized pharmaceutical formulation for the treatment of inflammatory diseases of the colon is disclosed, wherein the pharmaceutical formulation is a capsule containing pellets, which capsule is suitable for oral administration and delivers the active substance in a targeted manner to the site of action, namely the colon. This is achieved by a complex and multiple coating of pellets, which permit a modified release of active substance. The release of the active substance is at its maximum only in the colon, with at the same time low blood plasma levels. The results of the pharmaceutical tests concerning in vitro release are corroborated by the results in pharmaco-kinetic and clinical studies and the clinical efficacy demonstrated by these. The formulation according to the invention has a very good medicinal safety.
    Type: Application
    Filed: August 22, 2019
    Publication date: July 29, 2021
    Applicant: Dr. Falk Pharma GmbH
    Inventors: Rudolf WILHELM, Markus PROELS, Roland GREINWALD, Tanju NACAK, Ansgar BOEGERSHAUSEN
  • Patent number: 10905699
    Abstract: Disclosed is a storage-stable pharmaceutical formulation for rectal administration, containing budesonide or a pharmaceutically compatible salt or derivative thereof, and at least 80 wt % of a solid fat or a mixture of different solid fats, based on the total weight of the formulation, as well as at least one anti-oxidation agent that is compatible therewith.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: February 2, 2021
    Assignee: Dr. Falk Pharma GmbH
    Inventors: Rudolph Wilhelm, Markus Pröls, Roland Greinwald, Ralf Mohrbacher
  • Publication number: 20200337997
    Abstract: Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.
    Type: Application
    Filed: May 15, 2020
    Publication date: October 29, 2020
    Applicant: Dr. Falk Pharma GmbH
    Inventors: Roland GREINWALD, Ralph Mueller, Markus Proels, Rudolf Wilhelm
  • Patent number: 10695291
    Abstract: Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: June 30, 2020
    Assignee: Dr. Falk Pharma GmbH
    Inventors: Roland Greinwald, Ralph Mueller, Markus Proels, Rudolf Wilhelm
  • Publication number: 20190358155
    Abstract: Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.
    Type: Application
    Filed: June 17, 2019
    Publication date: November 28, 2019
    Applicant: Dr. Falk Pharma GmbH
    Inventors: Roland GREINWALD, Ralph MUELLER, Markus PROELS, Rudolf WILHELM
  • Patent number: 10369100
    Abstract: Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: August 6, 2019
    Assignee: Dr. Falk Pharma GmbH
    Inventors: Roland Greinwald, Ralph Mueller, Markus Proels, Rudolf Wilhelm
  • Publication number: 20180185277
    Abstract: Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.
    Type: Application
    Filed: December 6, 2017
    Publication date: July 5, 2018
    Applicant: Dr. Falk Pharma GmbH
    Inventors: Roland Greinwald, Ralph Mueller, Markus Proels, Rudolf Wilhelm
  • Patent number: 10000526
    Abstract: The present invention relates to a pure polymorph of Nor-UDCA or Bis-nor-UDCA, or of a pharmaceutically acceptable salt thereof. The invention further provides a pharmaceutical composition comprising the polymorph of the invention, and a method for preparing the polymorph. The invention includes the pharmaceutical use of the polymorph or of the pharmaceutical composition of the invention.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: June 19, 2018
    Assignee: Dr. Falk Pharma GmbH
    Inventors: Rudolf Wilhelm, Markus Pröls, Erik Fischer, Heidi Waenerlund Poulsen
  • Patent number: 9867780
    Abstract: Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: January 16, 2018
    Assignee: Dr. Falk Pharma GmbH
    Inventors: Roland Greinwald, Ralph Mueller, Markus Proels, Rudolf Wilhelm
  • Patent number: 9512167
    Abstract: The present invention relates to a pure polymorph of Nor-UDCA or Bis-nor-UDCA, or of a pharmaceutically acceptable salt thereof. The invention further provides a pharmaceutical composition comprising the polymorph of the invention, and a method for preparing the polymorph. The invention includes the pharmaceutical use of the polymorph or of the pharmaceutical composition of the invention.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: December 6, 2016
    Assignee: Dr. Falk Pharma GmbH
    Inventors: Rudolf Wilhelm, Markus Proels, Erik Fischer, Heidi Waenerlund Poulsen
  • Publication number: 20160324772
    Abstract: Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.
    Type: Application
    Filed: December 18, 2014
    Publication date: November 10, 2016
    Applicant: DR. FALK PHARMA GMBH
    Inventors: Roland GREINWALD, Ralph MUELLER, Markus PROELS, Rudolf WILHELM
  • Patent number: 9017700
    Abstract: The present application describes a novel, advantageous purification method which guarantees the embryonation capability and the viability of a worm egg suspension. The T. suis worm eggs are first treated in a non-embryonated condition in a sulfuric acid solution at about =ph 2. Bacteria and viruses are thereby killed successfully. The germination number of yeasts and fungi is reduced. In a second step, the pH-value is increased and an orally tolerated preservative is added. Yeasts and fungi are thereby killed successfully. The suspension medium used in the second purification step can then be used as a culture medium for additional production (embryonation) and storage.
    Type: Grant
    Filed: March 31, 2008
    Date of Patent: April 28, 2015
    Assignee: Dr. Falk Pharma GmbH
    Inventors: Rudolf Wilhelm, Allan Kund Roepstorff, Christian Moliin Outzen Kapel
  • Patent number: 8993332
    Abstract: A method for determining the biological activity of embryonated Trichuris eggs is described, in which at least one of the following determinations is carried out: a) Determination and/or confirmation of the stage of the embryonal development of helminth eggs with the aid of quantitative PCR analysis by using suitable marker sequences for ascertaining the copy number of the genomic DNA, b) Determination of the metabolic activity of embryonated helminth eggs by means of biochemical and/or molecular biological methods, c) Determination of the inducibility of gene expression in embryonated helminth eggs, d) Microscopic determination of the motility of helminth larvae in the egg over long periods of observation after pre-incubation at increased temperatures and/or e) Determination of the hatching rate of Trichuris larvae in a laboratory animal, wherein the intact embryonated eggs recovered from the contents of the intestine are quantified compared to an internal standard.
    Type: Grant
    Filed: May 20, 2009
    Date of Patent: March 31, 2015
    Assignee: Dr. Falk Pharma GmbH
    Inventors: Bernhard Tewes, Rudolf Wilhelm
  • Patent number: 8956647
    Abstract: An orally administrable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically tolerable salt or a derivative thereof.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: February 17, 2015
    Assignee: Dr. Falk Pharma GmbH
    Inventors: Norbert Otterbeck, Peter Gruber